astemizole has been researched along with atovaquone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Biagini, GA; Chandramohanadas, R; Darling, C; DeGrado, WF; Diamond, SL; Fisher, N; Greenbaum, DC; Jing, H; Jo, H; Lucumi, E; Napper, AD; Shone, AE; Ward, SA | 1 |
| Clardy, J; Derbyshire, ER; Mota, MM; Prudêncio, M | 1 |
3 other study(ies) available for astemizole and atovaquone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
Topics: Animals; Antimalarials; Drug Resistance, Multiple; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum | 2010 |
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
Topics: Animals; Anopheles; Antimalarials; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Inhibitory Concentration 50; Insect Vectors; Life Cycle Stages; Liver; Malaria; Malaria, Falciparum; Male; Mice; Mice, Inbred C57BL; Plasmodium berghei; Plasmodium falciparum; Treatment Outcome | 2012 |